Prediction of ROS1 and TRKA/B/C occupancy in plasma and cerebrospinal fluid for entrectinib alone and in DDIs using physiologically based pharmacokinetic (PBPK) modeling approach-Reference-Cited by-同舟云学术

Prediction of ROS1 and TRKA/B/C occupancy in plasma and cerebrospinal fluid for entrectinib alone and in DDIs using physiologically based pharmacokinetic (PBPK) modeling approach

Published:2023-10-14 Issue: Volume: Page:
ISSN:0344-5704
Container-title:Cancer Chemotherapy and Pharmacology
language:en
Short-container-title:Cancer Chemother Pharmacol

Author:

Chen Liangang,Yao Na,Yang Hongjie,Zhang Shaofeng,Zhang Kai^ORCID

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical),Cancer Research,Pharmacology,Toxicology,Oncology

Link

https://link.springer.com/content/pdf/10.1007/s00280-023-04598-5.pdf

Reference39 articles.

1. Thandra KC, Barsouk A, Saginala K et al (2021) Epidemiology of lung cancer. Contemp Oncol 25(1):45–52

2. Huang Y, Zhang LJCI (2023) Annual progress of clinical research on targeted therapy for nonsmall cell lung cancer in 2022. Cancer Innovation 2(1):25–35

3. Coleman N, Hong L, Zhang J et al (2021) Beyond epidermal growth factor receptor: MET amplification as a general resistance driver to targeted therapy in oncogene-driven non-small-cell lung cancer. ESMO Open 6(6):100319

4. Farago AF, Taylor MS, Doebele RC et al (2018) Clinicopathologic features of non–small-cell lung cancer harboring an NTRK gene fusion. JCO Precis Oncol 2:1–12

5. Demetri GD, De Braud F, Drilon A et al (2022) Updated integrated analysis of the efficacy and safety of entrectinib in patients with NTRK fusion-positive solid tumors. Clin Cancer Res.

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Inhibition of human UDP-glucuronosyltransferase enzyme by entrectinib: Implications for drug-drug interactions;Chemico-Biological Interactions;2024-05